Ranexa Target Population Is 10%-25% Of Angina Patients; Sampling Will Be Key
Executive Summary
CV Therapeutics' launch of its second-line angina product Ranexa (ranolazine) will include an aggressive sampling program
You may also be interested in...
CV Therapeutics Sets Sights On Imdur With Ranolazine Development
CV Therapeutics is looking at Schering-Plough's Imdur (isosorbide) as a market "benchmark" for its Phase III anti-angina agent ranolazine.
Innovex Sales Support For CVT Angina Drug Based On Percentage Formula
Quintiles' contract sales division Innovex would receive up to one-third of the first two years of sales from a chronic stable angina treatment being developed by CV Therapeutics, under a commercialization deal announced May 11.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011